Taiwan Pharmaceuticals and Healthcare Report Q4 2012

  • ID: 2221414
  • August 2012
  • Region: Taiwan
  • 98 pages
  • Business Monitor International

The Taiwan Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Taiwan's pharmaceuticals and healthcare industry.

BMI View:
Having been calculated to have reached TWD135.10bn (US$4.59bn) in 2011 sales, Taiwan’s pharmaceutical market is expected to post a compound annual growth rate (CAGR) of 3.3% in local currency terms to 2016, which is considerably below the historical (2006-2011) – and already modest - growth of 4.6%. While patented drugs comprise around two-thirds of the market, barriers to entry for research-based companies are considerable, and include unfavourable intellectual property (IP) and pricing and reimbursement climate. Nevertheless, we expect patented drugs to retain their market share over the next five years, partly due to concern over the use of generic medicines exists among patients.

Headline Expenditure Projections

- Pharmaceuticals: TWD135.10bn (US$4.59bn) in 2011 to TWD140.05bn (US$4.59bn) in 2012; +3.7% in local currency terms and -0.1% READ MORE >

Note: Product cover images may vary from those shown

Executive Summary 7

SWOT Analysis 9

Taiwan Pharmaceuticals And Healthcare Industry SWOT 9

Taiwan Political SWOT 10

Taiwan Economic SWOT 10

Taiwan Business Environment SWOT 11

Pharmaceutical Business Environment Ratings 12
Table: Asia Pacific – Regional Pharmaceutical Business Environment Ratings, Q412 12

Rewards 13

Risks 13

Taiwan – Market Summary 15

Regulatory Regime 16
Table: Examples Of Controlled Drugs In Taiwan 17
Table: Medicine Categories In Taiwan 18

Recent Regulatory Developments 18

Intellectual Property Regime 19

Intellectual Property Developments 21

Counterfeits 22

Pricing Regime 22

Reimbursement Regime 23
Table: Drug Reimbursement Principles 24
Table: BNHI Spending by Type of Outpatient Claims, as Percentage of Total 25

Recent Reimbursement Regime Developments 26

Free Trade Agreements 27

Industry Developments 28

Epidemiology 28

Non-Communicable Diseases 29

Communicable Diseases 30

Healthcare System 31

Healthcare Insurance 31

Healthcare Financing 32

Taiwan: Insurance Coverage 32

Recent Healthcare System Developments 33

Traditional Chinese Medicine 34

Biotechnology Sector 35

Recent Biotechnology Developments 36

Vaccines 38

Clinical Trials 38

Recent Clinical Trials Sector Developments 40

Medical Tourism 40

Medical Devices 41

Industry Forecast Scenario 44

Overall Market Forecast 44
Table: Pharmaceutical Sales Indicators 2008-2016 44

Healthcare Market Forecast 46
Table: Healthcare Expenditure Indicators 2008-2016 47
Table: Healthcare Governmental Indicators 2008-2016 48
Table: Healthcare Private Indicators 2008-2016 48

Key Growth Factors – Macroeconomic 50

Prescription Drug Market Forecast 52
Table: Prescription Drug Sales Indicators 2008-2016 53

Patented Drug Market Forecast 54
Table: Patented Drug Market Indicators 2008-2016 55

Generic Drug Market Forecast 56
Table: Generic Drug Sales Indicators 2008-2016 57

OTC Medicine Market Forecast 58
Table: OTC Medicine Sales Indicators 2008-2016 60

Pharmaceutical Trade Forecast 61
Table: Exports and Imports Indicators 2008-2016 62

Medical Device Market Forecast 63
Table: Medical Devices Sales Indicators 2008-2016 65

Other Healthcare Data Forecasts 66

Key Risks To our Forecast Scenario 67

Competitive Landscape 68

Pharmaceutical Industry 68

Leading Pharmaceutical Companies According To Market Capitalisation On The Taiwan Stock Exchange (TWSE) 69
Table: Top 10 Pharmaceuticals In Taiwan According To BNHI Expenditure During 2008 70

Domestic Pharmaceutical Sector 70

Recent Domestic Company Activities 71

Foreign Pharmaceutical Sector 72

Recent Foreign Company Activity 72

Pharmaceutical Distribution 73

Corporate Members Of Taiwan’s International Research-Based Pharmaceutical Manufacturers Association (IRPMA) 73

Company Profiles 75

Leading Domestic Companies 75

Yung Shin Pharmaceutical (YSP) 75

ScinoPharm Taiwan 77

Empax Pharma 79

Leading Multinationals 80

Pfizer 80

Sanofi 82

GlaxoSmithKline 84

Novartis 86

Merck & Co 88

Country Snapshot: Taiwan Demographic Data 90

Section 1: Population 90
Table: Demographic Indicators, 2000-2030 90

Section 2: Labour Market And Spending Power 91
Table: Employment Indicators, 2000-2005 91
Table: Consumer Expenditure, 2000-2005 (US$) 91
Table: Average Annual Manufacturing Wages, 2005-2012 91

Glossary 92

BMI Methodology 94

How We Generate Our Pharmaceutical Industry Forecasts 94

Pharmaceuticals Business Environment Ratings 95

Risk/Reward Ratings Methodology 95

Ratings Overview 95
Table: Pharmaceutical Business Environment Indicators 96

Weighting 97
Table: Weighting Of Components 97

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Pfizer, Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S